Assort Health Hits $222M — AI Patient Access Is the New Front-End RCM

Assort Health just closed a $120M Series C led by Menlo Ventures, bringing total funding to $222M. In the last 15 months, they grew revenue 20x. The signal here isn't the money — it's what the money is chasing.

$222M

Total funding raised by Assort Health · $120M Series C led by Menlo Ventures · 20x revenue growth in 15 months · 200M+ patient interactions on platform

What Assort Actually Does

Assort Health runs AI agents across the patient journey: scheduling, intake, referrals, medication refills, lab requests, and payments. They're not a point solution — they're a front-office operating layer built on 200 million specialty patient interactions, 62,000 care protocols, and 1.6 million decision pathways.

That dataset is the moat. General-purpose AI can handle generic scheduling. It can't navigate the nuance of a multi-specialty group's referral rules, payer-specific prior auth requirements, or specialty-specific scheduling constraints at scale. Assort has trained on that complexity for years.

The results they're publishing: 5% lift in appointment volume, 115% increase in labor capacity, 4.3/5 patient satisfaction. Those aren't pilot numbers — they're coming from multi-site practices and health systems running the platform in production.

The RCM Angle Everyone's Missing

Assort gets categorized as "patient access tech." That framing undersells it. Patient access is front-end RCM — it's where eligibility gets verified, prior auths get initiated, and patient financial responsibility gets communicated before a single claim is ever submitted.

When Assort automates scheduling and intake at scale, they're also capturing the data that downstream RCM depends on. Insurance is confirmed. Referral authorization is documented. Patient consent and demographics are collected correctly the first time. That's denial prevention at the source — before the claim exists.

What this means for denial rates

A meaningful chunk of claim denials trace back to front-end failures: wrong insurance on file, missing prior auth, patient eligibility not verified at time of service. Platforms like Assort that automate patient access correctly are reducing denial exposure before the back-end RCM team ever sees the claim.

The Exec Hires Signal Where They're Going

Alongside the funding announcement, Assort named three senior hires worth reading:

Jon Corn, CRO — came from Samsara, where he built the enterprise GTM that grew ARR 1,220% and landed the first Fortune 10 relationship. His job: land large health systems at scale.
Kristina Kemp, VP Customer Success — spent seven years at Luma Health making expansion revenue the largest growth driver. Her mandate is exactly that — land and expand inside existing health system accounts.
Emil Yeargin, SVP People — came from Gusto, Lyft, and Okta. They're building for headcount scale, not just product maturity.

This is a classic Series C buildout: hire the commercial infrastructure that a $120M raise demands. The CRO's background at Samsara — a company that scaled to Fortune 10 enterprise accounts — tells you exactly what kind of deals Assort is pursuing now. They're not selling into 10-physician groups anymore.

The Broader Pattern

Assort isn't alone. The AI patient access category has consolidated significant capital in the last 18 months. Luma Health, Relatient, Klara, and now Assort are all competing for the same front-office automation budget — and health systems are buying.

The consolidation pressure on traditional RCM vendors is real. If a platform can automate scheduling, intake, referrals, and payment collection with AI agents — and integrate natively with Epic and Athena — the question becomes: what exactly is the patient access coordinator doing? And after that: what is the front-end RCM biller doing?

The staffing implication

Assort's 115% labor capacity claim means one person doing the work of two-plus. At 20x revenue growth and $222M in capital, they have the resources to push that number higher. Front-end RCM roles tied to scheduling, intake, and insurance verification are in the crosshairs.

Bottom Line

$222M is a serious number for a category that was still considered experimental two years ago. The growth metrics are real. The hires are enterprise-grade. And the product is sitting exactly where the RCM industry's biggest pain point is: the front end, where errors create the denials that the back end spends enormous resources resolving.

If you run front-end RCM operations and you're not evaluating AI patient access platforms this year, you're going to be explaining to your CFO why your cost-to-collect is higher than your peers' next year.

Source: PRNewswire — Assort Health, July 21, 2026